REPROCELL Launches GMP iPSC Manufacturing Service
Analysis based on 9 articles · First reported Mar 03, 2026 · Last updated Mar 03, 2026
The launch of REPROCELL's GMP MCB manufacturing service is expected to positively impact the biotechnology and pharmaceutical markets by accelerating cell therapy development. This service, compliant with United States===Food and Drug Administration and International===European Medicines Agency standards, reduces regulatory uncertainty for developers, potentially leading to faster market entry for new therapies.
REPROCELL has launched its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs). This comprehensive, end-to-end workflow, operating from its Beltsville, Maryland facility, integrates StemRNA clinical seed iPSC manufacturing and StemEdit gene editing with GMP MCB production. The service aims to accelerate Investigational New Drug (IND) submissions for cell therapy developers by reducing regulatory and manufacturing uncertainty. A key component is the StemRNA Clinical iPSC Seed Clone - LLF-34-F3, derived from US sourced donor material and supported by an active United States===Food and Drug Administration Drug Master File (DMF). For European alignment, REPROCELL partners with Histocell, operating under Spain===Spanish Agency of Medicines and Medical Devices and International===European Medicines Agency oversight. This initiative is designed to provide reliable, regulatory-ready cell starting materials and services to academic, biotech, and pharmaceutical organizations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard